# Semaglutide (Ozempic, Rybelsus, Wegovy)

[Link to Decision Pathway](https://mygainwell-my.sharepoint.com/:w:/g/personal/cassandra_roach_gainwelltechnologies_com/EbkAQ5klIW1Olrx0WShhrA4BFgu1DO2Adg8vlpwbfguUsw?e=NQI3HS){ :target="_blank" rel="noopener"}

[Recording for Decision Pathway](https://mygainwell-my.sharepoint.com/:v:/r/personal/cassandra_roach_gainwelltechnologies_com/Documents/Recordings/Ozempic,%20Rybelsus%20and%20Wegovy%20(semaglutide)%20Decision%20Pathway-20230803_114810-Meeting%20Recording.mp4?csf=1&web=1&e=a11eHg&nav=eyJyZWZlcnJhbEluZm8iOnsicmVmZXJyYWxBcHAiOiJTdHJlYW1XZWJBcHAiLCJyZWZlcnJhbFZpZXciOiJTaGFyZURpYWxvZyIsInJlZmVycmFsQXBwUGxhdGZvcm0iOiJXZWIiLCJyZWZlcnJhbE1vZGUiOiJ2aWV3In19){ :target="_blank" rel="noopener"}

## Decision Pathway

Semaglutide (Ozempic, Rybelsus, Wegovy)

### 0998

<table>
    <tr>
        <th>Question ID</th>
        <th>Question Text</th>
        <th>Choice Text</th>
        <th>Next Question ID</th>
    </tr>
    <tr>
        <td rowspan="2">0998</td>
        <td rowspan="2">Is this an initial authorization or a reauthorization request?</td>
        <td>New Start (initial authorization request)</td>
        <td>0999</td>
    </tr>
    <tr>
        <td>Continuation (reauthorization request)</td>
        <td>1234</td>
    </tr>
</table>

### 0999

<table>
    <tr>
        <th>Question ID</th>
        <th>Question Text</th>
        <th>Choice Text</th>
        <th>Next Question ID</th>
    </tr>
    <tr>
        <td rowspan="2" >0999</td>
        <td rowspan="2" >Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? See FDA indications below:
            <table>
                <tr>
                    <td>Ozempic</td>
                    <td>
                        <ul>
                            <li>Adjunct to diet/exercise to improve glycemic control in <u><b>type 2 diabetes</u></b></li>
                            <li>To reduce risk of major adverse cardiovascular events in adults with <b><u>type 2 diabetes and established cardiovascular disease </br>**This does NOT include prediabetes or an A1C <7%**</b></u></li>
                        </ul>
                    </td>
                </tr>
                <tr>
                    <td>Rybelsus</td>
                    <td>
                        <ul>
                            <li>Adjunct to diet/exercise to improve glycemic control in adults with <u><b>type 2 diabetes </br>**This does NOT include prediabetes or an A1C<7%**</u></b></li>
                        </ul>
                    </td>
                </tr>
                <tr>
                    <td>Wegovy</td>
                    <td><u><b>STOP. This is an administrative denial.</u></b>Obesity drugs are not covered.</td>
                </tr>
            </table>
        </td>
        <td>Y</td>
        <td>1000</td>
    </tr>
    <tr>
        <td>N</td>
        <td>Sent to <u><b>MEDREVIEW</u></b> for a pharmacist to review/deny with language citing all criteria that is not met.</td>
    </tr>
</table>

### 1000

<table>
    <tr>
        <th>Question ID</th>
        <th>Question Text</th>
        <th>Choice Text</th>
        <th>Next Question ID</th>
    </tr>
    <tr>
        <td rowspan="2">1000</td>
        <td rowspan="2">Has the patient had an inadequate clinical response of at least <b><u>120 days</u> with at least <u>three preferred drugs</u> (one of those drug trials must be Byetta, Trulicity, or Victoza)</b>?
            <ul>
                <li>This must be supported by claims in VUE360 or medical records (which must include medication/strength/dates).</li>
                <li>An inadequate clinical response is defined as the inability to reach A1C goal (<7%) after at least 120 days of current regimen with documented adherence and appropriate dose escalation.</li>
                <li><i>If a medication dose was not increased over 120 days to reach a maintenance dose (and remains at a starting dose) and no explanation for lack of does increase is listed such as adverse event, this is not considered an adequate trial.</i></li>
            </ul>
            <table>
                <tr>
                    <th>Drug</th>
                    <th>Starting Dose</th>
                    <th>Maintenance Dose</th>
                </tr>
                <tr>
                    <td>Acarbose</td>
                    <td>25 mg TID</td>
                    <td>50-100 mg TID</td>
                </tr>
                <tr>
                    <td>Actoplus Met XR</td>
                    <td>15-30 mg/1g once daily</td>
                    <td>15 mg/1g BID <b>-or-</b> 30mg/2g once daily</td>
                </tr>
                <tr>
                    <td>Byetta</td>
                    <td>5 mcg BID</td>
                    <td>5-10 mcg BID</td>
                </tr>
                <tr>
                    <td>Farxiga</td>
                    <td>5 mg once daily</td>
                    <td>10 mg once daily</td>
                </tr>
                <tr>
                    <td>Glimepiride</td>
                    <td>1-2 mg once daily</td>
                    <td>2-4 mg/day</td>
                </tr>
                <tr>
                    <td>Glipizide</td>
                    <td>2.5-5 mg once daily</td>
                    <td>2.5-10 mg/day</td>
                </tr>
                <tr>
                    <td>Glipizide/Metformin</td>
                    <td>Uncontrolled on diet and exercise alone: 2.5/250 mg once daily <b>-or-</b> 2.5/500 mg BID (if FBG is 280-320) </br>Uncontrolled on sulfonylurea or metformin: 2.5/500 mg <b>-or-</b> 5/500 mg BID</td>
                    <td>2.5-20 mg/2 g per day</td>
                </tr>
                <tr>
                    <td>Glyburide</td>
                    <td>Conventional tabs: 1.25-5 mg once daily</br>Micronized tabs: 0.75-3 mg once daily</td>
                    <td>Conventional tabs: 2.5-10 mg/day</br>Micronized tabs: 0.75-6 mg/day</td>
                </tr>
                <tr>
                    <td>Glyburide/Metformin</td>
                    <td>Uncontrolled on diet and exercise alone: 1.25/250 mg once or BID</b>Uncontrolled on sulfonylurea or metformin: 2.5/500 mg <b>-or-</b>5/500 mg BID</td>
                    <td>1.25-20 mg/2 g per day</td>
                </tr>
                <tr>
                    <td>Invokamet</td>
                    <td>100 mg/1 g in 2 divided doses (IR) or once daily (ER)</td>
                    <td>100-300 mg/2 g per day</td>
                </tr>
                <tr>
                    <td>Invokana</td>
                    <td>100 mg once daily</td>
                    <td>100-300 mg once daily</td>
                </tr>
                <tr>
                    <td>Janumet</td>
                    <td>100 mg/1 g in 2 divided doses</td>
                    <td>100 mg/2 g in 2 didvided doses</td>
                </tr>
                <tr>
                    <td>Janumet XR</td>
                    <td>100 mg/1 g once daily</td>
                    <td>1 mg/2 g once daily</td>
                <tr>
                    <td>Januvia</td>
                    <td>100 mg once daily</td>
                    <td>100 mg once daily</td>
                </tr>
                <tr>
                    <td>Jardiance</td>
                    <td>10 mg once daily</td>
                    <td>10-25 mg once daily</td>
                </tr>
                <tr>
                    <td>Jentadueto</td>
                    <td>IR: 2.5/500-1000 mg BID</br>ER: 5 mg/1-2 g once daily</td>
                    <td>IR: 2.5/1000 mg BID</br>ER: 5 mg/2 g once daily</td>
                </tr>
                <tr>
                    <td>Metformin IR, ER</td>
                    <td>IR: 500 mg once or BID <b>-or-</b> 850 mg once daily</br>ER: 500 mg- 1 g once daily</td>
                    <td>IR: 1 g BID <b>-or-</b>850 mg BID</br>ER: 2 g once daily</td>
                <tr>
                    <td>Miglitol</td>
                    <td>25 mg TID</td>
                    <td>50 mg TID</td>
                </tr>
                <tr>
                    <td>Nateglinide</td>
                    <td>60-120 mg up to TID</td>
                    <td>60-120 mg up to TID</td>
                </tr>
                <tr>
                    <td>Pioglitazone</td>
                    <td>15-30 mg once daily</td>
                    <td>15-45 mg once daily</td>
                </tr>
                <tr>
                    <td>Pioglitazone/Metformin</td>
                    <td>15/500 mg BID <b>-or-</b> 15/850 mg once daily (ER)</td>
                    <td>15-45 mg/850 mg- 2.55 g per day</td>
                </tr>
                <tr>
                    <td>Repaglinide</td>
                    <td>A1c < 8%: 0.5 mg up to QID</br>A1c â‰¥ 8%: 1-2 mg up to QID</td>
                    <td>.5-1 mg TID</td>
                </tr>
                <tr>
                    <td>Repaglinide/Metformin</td>
                    <td>1/500 mg BID</td>
                    <td>1-4 mg/1 g BID</td>
                </tr>
                <tr>
                    <td>Synjardy</td>
                    <td>10 mg/ 1 g in 2 divided doses (IR) or once daily (ER)</td>
                    <td>10-25 mg/2 g per day</td>
                </tr>
                <tr>
                    <td>Tradjenta</td>
                    <td>5 mg once daily</td>
                    <td>5 mg once daily</td>
                </tr>
                <tr>
                    <td>Trulicity</td>
                    <td>0.75 mg once weekly</td>
                    <td>0.75-4.5 mg once weekly</td>
                </tr>
                <tr>
                    <td>Victoza</td>
                    <td>0.6 mg once daily</td>
                    <td>1.2-1.8 mg once daily</td>
                </tr>
            </table>
        </td>
        <td>Y</td>
        <td><b><u>Approve x 365 days.</b></u></td>
    </tr>
    <tr>
        <td>N</td>
        <td>1001</td>
    </tr>
</table>

### 1001

<table>
    <tr>
        <td rowspan="2">1001</td>
        <td rowspan="2">Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</td>
        <td>Y</td>
        <td>Send to <u><b>MEDREVIEW</u></b>for a pharmacist to evaluate on a case-by-case basis.</td>
    </tr>
    <tr>
        <td>N</td>
        <td>1002</td>
    </tr>
</table>

### 1002

<table>
    <tr>
        <td rowspan="2">1002</td>
        <td rowspan="2">From the submitted documentation, does the patient have a condition that is difficult to control (i.e., prone to ketoacidosis, hypoglycemia)?</td>
        <td>Y</td>
        <td>Send to <b><u>MEDREVIEW</b></u> for a pharmacist to evaluate on a case-by-case basis.</td>
    </tr>
    <tr>
        <td>N</td>
        <td>Send to <b><u>MEDREVIEW</b></u> for a pharmacist to review/deny with language citing all criteria that is not met.</td>
    </tr>
</table>

# 1234

<table>
    <tr>
        <td rowspan="2">1234</td>
        <td rowspan="2">
            <ol>
                <li>Confirm this is a reauthorization and an already approved PA with an authorization number (NOT an iPA) is on file.</li>
                <li>Confirm the provider submitted documentation of the patient's clinical response to treatment and ongoing safety monitoring.</li>
                    <ul>
                        <li>Efficacy monitoring: A1c since last approved PA.</li>
                        <li>Safety monitoring may not be mentioned if there are no current concerns or adverse events the patient is experiencing. This is ok.</li>
                    </ul>
            </ol>
        </td>
        <td>Y</td>
        <td><u><b>Approve x 365 days.</b></u></td>
    </tr>
    <tr>
        <td>N</td>
        <td>Sent to <u><b>MEDREVIEW</u></b> to deny with verbiage: <i>For a reauthorization, documentation of clinical response to treatment and ongoing safety monitoring is required.</i></td>
    </tr>
</table>
